Study Details

Back to Search Results

A multiple-dose study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT03260322

Astellas Study ID

The unique identification code given by the study sponsor.

8374-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2018-001146-34

Follow Trial

Condition

Advanced/Metastatic Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2017 - May 2022

Masking

None (Open Label)

Enrollment number

169

A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A multiple-dose study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site IT39013

Pisa, Italy

Honor Health Research Institute

Scottsdale, United States, 85258

Site IT39009

Milano, Italy

Site GB44006

London, United Kingdom

Site CA15004

Edmonton, Canada, T6G 1Z2

Mary Crowley Research Center

Dallas, United States, 75251

Fox Chase Cancer Center

Philadelphia, United States, 19111

Site KR82001

Seoul, Republic of Korea, 03080

University of Pittsburgh Cancer Institute

Pittsburgh, United States, 15232

Site GB44001

Leeds, United Kingdom

Site TW88603

Taipei City, Taiwan, Province of China

Site IT39010

Modena, Italy

Site TW88602

Taichung, Taiwan, Province of China, 00404

Site IT39007

Siena, Italy

Site CA15002

Montreal, Canada, H3T 1E2

Site IT39008

Milano, Italy

Huntsman Cancer Institute

Salt Lake City, United States, 84112

Site PT35106

Porto, Portugal

Site ES34009

Barcelona, Spain

Henry Ford Health System

Detroit, United States, 48202

Site ES34001

Madrid, Spain

University of California, San Francisco

San Francisco, United States, 94115

Site GB44004

Newcastle upon Tyne, United Kingdom

Site IT39012

Meldola, Italy

Site GB44005

Sutton Surry, United Kingdom

Icahn School of Medicine at Mount Sinai

New York, United States, 10029

Site IT39004

Ancona, Italy

University of Kansas Cancer Center

Fairway, United States, 66205

Virginia Cancer Specialists

Fairfax, United States, 22031

Site GB44003

London, United Kingdom

Mount Sinai Comprehensive Cancer Center

Miami Beach, United States, 33140

Site CA15001

Toronto, Canada, M5G 2M9

Site KR82005

Seongnam-Si, Republic of Korea, 013620

SIte KR82002

Seoul, Republic of Korea, 120-752

Site KR82004

Goyang-si, Republic of Korea, 410-769

Site ES34006

Madrid, Spain

Cedars-Sinai Medical Center

Los Angeles, United States, 90048

Medical College of Wisconsin

Milwaukee, United States, 53226-3522

University Hospital of Cleveland

Cleveland, United States, 44106

Site IT39011

Negrar, Italy

Site ES34002

Barcelona, Spain

Columbia University Medical Center

New York, United States, 10032

Site KR82006

Seoul, Republic of Korea

Site ES34010

Barcelona, Spain

Site JP81001

Chuo-ku, Japan

Site ES34013

Madrid, Spain

University of Iowa Hospitals and Clinics

Iowa City, United States, 52242

University of Arizona

Tucson, United States, 85719

University of California, Davis

Sacramento, United States, 95817

Site ES34003

Barcelona, Spain

Site ES34014

Valencia, Spain

Site IT39003

Milano, Italy

Site PT35101

Lisboa, Portugal

Sarah Cannon Research Institute

Nashville, United States, 37203

Karmanos Cancer Institute

Detroit, United States, 48201

Site IT39005

Monza, Italy

Site CA15003

Toronto, Canada, M4N 3M5

University of California Los Angeles

Los Angeles, United States, 90095

University of North Carolina

Chapel Hill, United States, 27599

Site TW88601

Tainan, Taiwan, Province of China

Site IT39002

Milano, Italy

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo